Toward this end, we strive to strengthen our competitiveness in key business fields through new drug development as we build corporate value through synergistic expansion.
We have a full-range of development programs spanning pre-clinical to phase 3 studies. This and our partnerships with more than 30 pharmaceutical firms and biotech ventures worldwide play a key role in our ongoing efforts to develop innovative new drug candidates and grow our pipeline.
Through Contera Pharma, a Denmark-based biotech specializing in the central nervous system (CNS), we are advancing the development of treatments for Parkinson’s disease morning akinesia and RNA-based therapeutics. Concurrently, we are focusing our capabilities on developing novel immunotherapy based on aryl hydrocarbon receptor (AhR) antagonists through Jaguar Therapeutics, a biotech company located in Singapore.
Our open innovation strategy drives our drug development pipeline. Profits generated by our pipeline are reinvested, creating a virtuous cycle that is enabling us to build a sustainable drug development model.
In addition to ethical drugs, we continue to expand our portfolio of consumer health products encompassing over-the-counter drugs, nutraceuticals, and personal care products.